Lifestance Health Group stock hits 52-week high at $8.11
Lifestance Health Group Inc. (LFST) stock reached a 52-week high of $8.11, with shares trading at $8.14 and a market capitalization of $3.08 billion, reflecting a 33.58% 1-year total return. InvestingPro analysis suggests the stock is undervalued, offering additional upside. Recent developments include its addition to the S&P SmallCap 600 index and increased price targets from Barclays and KeyBanc.
LifeStance Q1 2026 presentation: 21% revenue growth, guidance raised
LifeStance Health Group Inc. reported strong first-quarter 2026 results, exceeding market expectations with 21% year-over-year revenue growth and substantial margin expansion. The mental healthcare provider raised its full-year financial guidance for 2026, anticipating continued growth and improved profitability. The company's stock rose significantly in pre-market trading following the positive earnings and outlook.
Does LifeStance Health (LFST) Losing Russell Index Spots Recast Its Role in Investors’ Portfolios?
LifeStance Health Group (LFST) was removed from several Russell indices in late June 2026, which may impact how passive funds and benchmark-aware investors engage with the stock. While the company has shown positive fundamentals, including profitability and raised revenue guidance, the index removal combined with a "richer valuation" could shift investor focus from index-driven flows back to core fundamentals. This situation highlights the importance of considering multiple perspectives on the company's investment narrative and future investor positioning.
LifeStance Health Stock 9-Day Winning Spree: Stock Climbs 33%
LifeStance Health (LFST) stock experienced a 9-day winning streak, resulting in a 33% increase and a market cap surge of $1.1 billion to $4.4 billion. Despite this rally, the article suggests the stock is "Unattractive" due to moderate operating performance, financial condition, and high valuation, advocating for predictive signals over post-event notifications for investment decisions. The performance data shows LFST outperforming the S&P 500 across various periods, highlighting its volatility and potential for sharp reversals.
Does LifeStance Health (LFST) Losing Russell Index Spots Recast Its Role in Investors’ Portfolios?
LifeStance Health Group (LFST) was removed from several Russell indices, including the Russell 2000 Growth-Defensive, in late June 2026. This index exit could impact how passive funds and benchmark-aware investors engage with the stock, shifting focus from index-driven flows to fundamentals like revenue growth and margin progress. Investors are advised to closely watch the combination of richer valuation and index removal, considering differing fair value estimates and potential risks.
LifeStance (LFST) director-linked LLCs sell 894k shares at $10.13 average
Entities linked to LifeStance Health Group director Robert Bessler, specifically Shama LLC and Vitthal LLC, sold a total of 894,337 shares of LFST common stock on June 26, 2026, at a weighted average price of $10.13 per share. These open-market transactions, filed via a Form 4, occurred within a price range of $10.00 to $10.295. Despite these sales, the linked LLCs and Bessler's direct holdings still retain substantial positions in the company.
LifeStance Health Group, Inc.(NasdaqGS:LFST) dropped from Russell 2000 Defensive Index
LifeStance Health Group, Inc. (NasdaqGS:LFST) has been removed from the Russell 2000 Defensive Index, as well as several other Russell indices including the Russell 2000 Value Benchmark and Russell Small Cap Comp Value Benchmark. The company, which provides virtual and in-person outpatient mental healthcare, was also dropped from the Russell 2000 Value-Defensive and Growth-Defensive Indices. This news follows a series of recent events for the company, including a secondary stock offering and an analyst rating adjustment.
LifeStance Health Group, Inc.(NasdaqGS:LFST) dropped from Russell 3000 Value Benchmark
LifeStance Health Group, Inc. (NasdaqGS: LFST) has been removed from the Russell 3000 Value Benchmark. This news follows a series of other announcements where the company was dropped from various Russell indices, including the Russell 2000 Defensive Index and Russell Small Cap Comp Value Benchmark, all occurring around late June 2026. The company, which provides virtual and in-person outpatient mental healthcare, has recently seen its stock price change by +60.09% since January 1st, 2026, though it experienced a -1.40% change over the last 5 days.
LifeStance Health Group, Inc.(NasdaqGS:LFST) dropped from Russell 2000 Value Benchmark
LifeStance Health Group, Inc. (NasdaqGS:LFST) has been removed from the Russell 2000 Value Benchmark, according to an announcement on June 29, 2026. This is one of several recent index changes for the company, including being dropped from the Russell 2000 Defensive Index and Russell Small Cap Comp Value Benchmark on the same date or the day prior. LifeStance Health Group specializes in virtual and in-person mental healthcare services.
LifeStance Health Group, Inc.(NasdaqGS:LFST) dropped from Russell Small Cap Comp Value Benchmark
LifeStance Health Group, Inc. (NasdaqGS:LFST) has been removed from the Russell Small Cap Comp Value Benchmark, among other Russell indices, effective June 28-29, 2026. The company, which focuses on virtual and in-person mental healthcare, has experienced several such removals from Russell indices around the same time. This news follows recent financial activity including a secondary stock offering and a target price adjustment by UBS.
Lifestance Health Group stock hits 52-week high at $10.01
Lifestance Health Group Inc. (LFST) has reached a new 52-week high of $10.01, marking a 93.98% increase over the past year. The company recently completed a public offering of 35 million shares by existing stockholders and plans to repurchase 6 million shares from them. Goldman Sachs initiated coverage with a Neutral rating and a $9.00 price target.
Lifestance Health Group stock hits 52-week high at $10.01
Lifestance Health Group (LFST) stock recently hit a 52-week high of $10.01, reflecting a nearly 94% increase over the past year. The mental health services provider, with a market cap of $3.87 billion, is considered undervalued by InvestingPro and has seen analysts revise earnings expectations upwards. Despite this growth, recent news indicates an ongoing secondary offering where existing stockholders sold 35 million shares, and Goldman Sachs initiated coverage with a Neutral rating and a $9.00 price target.
Price to earnings forward of LifeStance Health Group, Inc. – NASDAQ:LFST
This article provides pricing and financial information for LifeStance Health Group, Inc. (NASDAQ: LFST) on TradingView. It outlines how to access financial data, news, and technical analysis for the company. The content also details various features and services offered by TradingView related to market analysis and trading education.
Lifestance Health Group stock hits 52-week high at $10.01 By Investing.com
Lifestance Health Group (LFST) has reached a new 52-week high of $10.01, demonstrating a 93.98% increase in its stock price over the past year. This surge follows significant events including an underwritten public offering by existing stockholders and an initiation of coverage by Goldman Sachs with a Neutral rating. The company, valued at $3.87 billion with 16.5% revenue growth, is attracting optimistic market attention.
Insiders sell LifeStance Health shares (NASDAQ: LFST) totaling $1.17M
LifeStance Health Group (NASDAQ: LFST) insiders reported sales of common stock totaling approximately $1.17 million across four transactions in April and May 2026. The sales were made by related holders, involving 5,101, 7,752, 62,147, and 75,000 shares, with proceeds ranging from $35,749.48 to $641,580.00. The filing also indicates 387,834,432 shares outstanding as of June 26, 2026.
Lifestance Health Group stock hits 52-week high at $10.01 By Investing.com
Lifestance Health Group's stock reached a 52-week high of $10.01, marking a significant 93.98% increase over the past year. The company, a mental health services provider with a $3.87 billion market cap, trades below its Fair Value according to InvestingPro data. Recent financial activities include an underwritten public offering by existing stockholders and coverage initiation by Goldman Sachs with a Neutral rating.
Lifestance Health Group, Inc. Actuals & Estimates (NASDAQ:LFST)
This article provides an overview of LifeStance Health Group, Inc. (NASDAQ:LFST) stock, including its current price, historical performance, and analyst forecasts. It details financial actuals and estimates, revenue, net income, and upcoming earnings report dates, while also addressing frequently asked questions about the company's stock.
LFST Forecast — Price Target — Prediction for 2027
This article provides a forecast for LifeStance Health Group, Inc. (LFST) stock, including analyst price targets, past performance, and financial metrics. It highlights that analysts have a maximum price estimate of $13.00 and a minimum of $9.00, and discusses the company's recent earnings, revenue, and market capitalization. The article also touches on volatility, employee count, EBITDA, and technical analysis ratings.
Lifestance Health Group stock hits 52-week high at $8.90 By Investing.com
LifeStance Health Group (LFST) stock recently hit a 52-week high of $8.90, representing a 79.72% increase over the past year and indicating strong investor confidence. The company's market capitalization is now $3.44 billion, and InvestingPro analysis suggests the stock is undervalued. This achievement follows a public offering where selling stockholders divested 35 million shares and Goldman Sachs initiated coverage with a "Neutral" rating.
Lifestance Health Group stock hits 52-week high at $8.90
Lifestance Health Group Inc. (LFST) has reached a new 52-week high of $8.90, marking a 79.72% increase over the past year. The company's market capitalization is now $3.44 billion, and InvestingPro analysis suggests the stock is undervalued. Recent activities include a public offering by selling stockholders and Goldman Sachs initiating coverage with a Neutral rating and a $9.00 price target.
LifeStance Health (LFST) Upgraded to Strong Buy: Here's What You Should Know
LifeStance Health (LFST) has been upgraded to a Zacks Rank #1 (Strong Buy) due to an upward trend in its earnings estimates, which is considered a powerful indicator for stock price movement. The Zacks system highlights the importance of changing earnings pictures, reflecting positivity in the company's outlook. This upgrade suggests that the stock is a solid candidate for market-beating returns given its superior earnings estimate revision feature.
Lifestance Health Group Inc (LFST) Financial Health: Profitability & Balance Sheet Analysis
Lifestance Health Group Inc (LFST) demonstrates robust financial health with a score of 8.89, ranking 12th in its industry. The company reported a significant year-over-year revenue increase of 21.17% and a net profit surge of 1908.89%. Despite positive indicators, some specific financial data points like total assets, total liabilities, and free cash flow were not disclosed, impacting detailed analysis of quality of earnings, operational efficiency, growth potential, and shareholder returns.
Lifestance Health Group Inc (LFST) Institutional Confidence
The article analyzes the institutional confidence score for Lifestance Health Group Inc (LFST), which currently stands at 10.00, placing it first in the Healthcare Providers & Services industry. Institutional shareholding has increased by 7.20% quarter-over-quarter, with First Eagle Investment being the largest holder. The report details the top institutional shareholders and their recent activity.
Lifestance Health Group Inc (LFST) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides an overview of Lifestance Health Group Inc (LFST) focusing on its historical dividend payouts and stock split events. It indicates that the company has not distributed dividends in the past five years and has no recorded stock split data. The current stock price and market capitalization are also presented.
Lifestance Health Group Inc (LFST) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Lifestance Health Group Inc (LFST), highlighting major shareholders and institutional holdings. TPG Capital, Fidelity Management & Research Company LLC, and Summit Partners, L.P. are identified as the largest shareholders, with private equity firms holding the largest proportion of shares by type. The report also provides a quarterly breakdown of institutional shareholding and recent shareholder activity.
LifeStance (LFST) CTO has shares withheld to cover RSU tax bill
LifeStance Health Group's CTO, Vukasin Paunovich, had 17,456 shares withheld by the company to cover tax obligations related to vested Restricted Stock Units (RSUs) on June 11, 2026. Priced at $8.61 per share, this was a net settlement and not an open-market sale. Following this transaction, Paunovich directly holds 291,840 shares of LifeStance common stock.
Wall Street Analysts See a 31.02% Upside in LifeStance Health (LFST): Can the Stock Really Move This High?
Wall Street analysts project a 31.02% upside for LifeStance Health (LFST), with a mean price target of $10.39, despite the stock having gained 21.8% recently. While a strong consensus price target and positive earnings estimate revisions suggest potential growth, the article cautions investors to treat price targets with skepticism, emphasizing that business incentives can lead to overly optimistic forecasts, but also noting that a low standard deviation in targets and a Zacks Rank #1 signify strong potential.
LifeStance Deadline Alert
Faruqi & Faruqi, LLP is investigating potential claims against LifeStance Health Group, Inc. (NASDAQ: LFST) and reminds investors of the October 11, 2022 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit. The lawsuit alleges that LifeStance and its executives made false and/or misleading statements regarding the company's business metrics and financial prospects, leading to significant losses for investors who purchased stock in the June 2021 IPO. Investors who suffered losses exceeding $100,000 are encouraged to contact the firm.
LifeStance Health Group (NasdaqGS:LFST) Stock Forecast & Analyst Predictions
LifeStance Health Group (LFST) is forecast to significantly grow earnings and revenue, with EPS expected to increase by 49.7% annually and revenue by 13.5%. Recent updates indicate improved EPS estimates for 2026, increased revenue forecasts, and a raised consensus price target. The company also reported strong Q1 2026 results with increased revenue, net income, and a lifted full-year guidance, alongside continued investments in AI and expansions.
Lifestance Shareholders Reaffirm Board, Auditor and Executive Pay
LifeStance Health Group (LFST) stockholders re-elected two Class II directors, ratified their independent auditor, and approved executive compensation on a non-binding basis during their annual meeting on June 2, 2026. This strong support indicates stability in the company's strategic direction and leadership. Despite a "Hold" analyst rating, TipRanks' AI Analyst, Spark, rates LFST as "Outperform" due to improving fundamentals, strong free cash flow, and raised 2026 guidance, though it notes valuation as an offset.
Goldman Sachs initiates Lifestance Health stock at neutral
Goldman Sachs has initiated coverage on Lifestance Health Group (NASDAQ:LFST) with a Neutral rating and a $9.00 price target. The firm notes that Lifestance, a major provider of outpatient mental health services, is well-positioned due to rising demand for behavioral health and a shift towards lower-cost care; however, its growth is tied to clinician capacity and retention. The Neutral rating reflects the shift in focus from demand to consistent capacity growth and sustainable margin improvement.
Goldman initiated coverage on LifeStance Health Group with a new price target
Goldman Sachs has initiated coverage on LifeStance Health Group (LFST) with a new price target. This analyst rating was quickly disseminated to Quantisnow Plus members. The article also highlights recent insider trading activity for LFST, showing multiple large share sales by directors and a major owner.
Goldman Sachs initiates Lifestance Health stock at neutral
Goldman Sachs has initiated coverage on Lifestance Health Group (NASDAQ:LFST) with a Neutral rating and a $9.00 price target. The firm noted Lifestance's favorable position in the behavioral health market due to increasing demand and shifts towards outpatient care. Despite solid revenue growth, Goldman Sachs' rating reflects a focus on consistent capacity growth and sustainable margin improvement.
LifeStance (NASDAQ: LFST) investors approve directors, executive pay and PwC
LifeStance Health Group, Inc. (NASDAQ: LFST) held its annual stockholder meeting on June 2, 2026, where investors approved all three proposals. Stockholders elected David Bourdon and Robert Bessler as Class II directors for three-year terms and ratified PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2026. Additionally, shareholders approved, on a non-binding advisory basis, the compensation for the company’s named executive officers.
LFST Stock Price, Quote & Chart | LIFESTANCE HEALTH GROUP INC (NASDAQ:LFST)
This article provides an in-depth financial overview of LIFESTANCE HEALTH GROUP INC (NASDAQ:LFST), detailing its current stock price, performance, key statistics, and analyst forecasts. It highlights the company's strong revenue growth, technical strength with a ChartMill rating of 10/10, and recent earnings beat. The report also includes fundamental analysis, ownership details, industry comparisons, and recent news related to LFST.
Serial Buyers LifeStance, ARC Health, Beacon Behavioral Reveal Their Acquisition Playbooks for 2026
LifeStance Health, ARC Health, and Beacon Behavioral Partners have refined their acquisition strategies, shifting from pure growth to focusing on integration, fit, and sustainability. LifeStance is returning to M&A with a focus on tuck-in deals that expand outpatient footprints and service lines, while ARC Health and Beacon Behavioral are prioritizing strong partner alignment and clinical quality. All three companies emphasize culture and compliance fit, and avoid targets with weak compliance, low scalability, or those outside their specialized outpatient mental health focus.
3 Reasons to Avoid LFST and 1 Stock to Buy Instead
This article analyzes why investors should be cautious about LifeStance Health Group (LFST), despite its recent stock price increase. The author outlines three reasons: limited distribution channels due to its small size, breakeven free cash flow hindering reinvestment, and negative return on invested capital from past growth initiatives. The article concludes that LFST's business quality is subpar and suggests investing in a more established, "all-weather" company instead, mentioning the owner of Taco Bell.
Preliminary Approval Granted in LifeStance Data Privacy Case
A federal court in Arizona has granted preliminary approval for a class action settlement in the Strong v. LifeStance Health Group Inc. data privacy case. The lawsuit alleged that LifeStance disclosed patients' personal information through website tracking technologies. The settlement includes two subclasses of LifeStance's patient population, and a final approval hearing is scheduled for October 2, 2026.
LifeStance Health Group (LFST) is a great momentum stock: Should you buy?
This article asks whether LifeStance Health Group (LFST) is a good momentum stock to buy. It likely analyzes the company's recent stock performance and valuation to determine its investment potential.
TPG entities listed with 29.3% of LifeStance (LFST) common stock
TPG-affiliated entities, including TPG GP A, LLC, James G. Coulter, and Jon Winkelried, have reported a 29.3% stake in LifeStance Health Group, Inc. (LFST) through an amended Schedule 13G/A filing. This includes 111,744,614 shares of common stock, with shared voting and shared dispositive power, based on 381,834,432 shares outstanding as of May 12, 2026. The filing highlights the ownership structure through TPG VIII Lynnwood and disclaims beneficial ownership beyond pecuniary interest for the individual reporting persons.
Summit funds tied to LifeStance (LFST) director sell 5.9M shares
LifeStance Health Group, Inc. director Darren M. Black reported an indirect open-market sale of 5,899,661 shares of common stock at $8.02 per share through Summit Partners-affiliated investment entities. After these transactions, the entities collectively hold 23,310,115 shares. The sale, valued at over $47 million, was completed on May 12, 2026, and was reported via a Form 4 SEC filing.
Insider Selling: LifeStance Health Group (NASDAQ:LFST) Director Sells 575,034 Shares of Stock
LifeStance Health Group (NASDAQ:LFST) director Robert Bessler recently sold 575,034 shares of the company's stock for approximately $4.61 million, reducing his ownership by 36.81%. This sale follows other transactions by Bessler in April and May. Despite these insider sales, analysts maintain a "Buy" consensus rating for LFST with an average price target of $9.86, following strong first-quarter results and a $100 million share buyback authorization.
LifeStance Health director Darren Black sells $47.3m in stock
LifeStance Health Group director Darren M. Black indirectly sold 5,899,661 shares of common stock for approximately $47.3 million through various Summit Partners funds. Following the sale, entities beneficially owned by Mr. Black still hold over 23 million shares. The transaction occurred as the stock experienced a challenging week with an 11% decline, despite strong six-month and one-year returns, and an InvestingPro analysis suggesting it remains undervalued.
LifeStance Health director Darren Black sells $47.3m in stock
Darren M. Black, a director at LifeStance Health Group, Inc. (NASDAQ:LFST), indirectly sold over 5.8 million shares of common stock for approximately $47.3 million. The transaction, executed through various Summit Partners funds, occurred on May 12, 2026, with shares priced at $8.02. Despite a recent weekly decline, the stock has shown strong six-month and year-over-year returns, and InvestingPro suggests it remains undervalued.
LifeStance Health director Robert Bessler sells $4.6m in shares
LifeStance Health Group director Robert Bessler sold approximately $4.61 million worth of common stock on May 12, 2026, through indirect holdings. This sale, at $8.02 per share, comes despite the company's recent strong Q1 2026 financial results, which included an earnings per share of $0.04 and revenue of $403.48 million, both exceeding expectations. Bessler retains significant indirect and direct holdings in the company after these transactions.
LifeStance Health director Eric Shuey sells $1.95m in stock
LifeStance Health director Eric Shuey sold 243,362 shares of common stock for approximately $1.95 million. The sale was made on May 12, 2026, by the Eric Shuey Gift Trust, reducing its holdings to 867,562 shares. Despite a recent stock decline, shares are up 41% over the past year, and the company recently reported strong Q1 2026 financial results.
Director-linked LLCs trim LifeStance (LFST) stakes with 575,034-share sale
LifeStance Health Group director Robert Bessler's associated entities, Shama LLC and Vitthal LLC, collectively sold 575,034 shares of LFST common stock at $8.02 per share on May 12, 2026. These indirect open-market sales amounted to over $4.6 million. Following the transactions, the LLCs still hold significant stakes in the company, though Bessler disclaims beneficial ownership except to the extent of his pecuniary interest.
[Form 4] LifeStance Health Group, Inc. Insider Trading Activity
A Form 4 filing revealed that the Eric Shuey Gift Trust, linked to LifeStance Health Group director Eric Shuey, sold 243,362 shares of LifeStance common stock at $8.02 per share in an open-market transaction. Following this sale, the trust indirectly holds 867,562 shares, while Eric Shuey directly holds 93,982 shares. Shuey disclaims beneficial ownership of the trust-held securities except for his pecuniary interest.
5 Revealing Analyst Questions From LifeStance Health Group’s Q1 Earnings Call
LifeStance Health Group's Q1 results showed strong revenue growth and margin expansion, driven by clinician recruitment, productivity, and technology use. The company raised its full-year revenue and EBITDA guidance. This article highlights five key analyst questions and management's answers regarding clinician growth, productivity, patient conversion, leveraging clinical outcomes, and expansion strategies.
Vanguard Group Inc. Raises Position in LifeStance Health Group, Inc. $LFST
Vanguard Group Inc. significantly increased its stake in LifeStance Health Group (NASDAQ:LFST) by 21.1% in the fourth quarter, bringing its total holdings to 17.7 million shares valued at $124.6 million. This increase happened despite notable insider selling from directors, with the company also reporting better-than-expected first-quarter earnings and authorizing a $100 million share repurchase program. Analysts currently have a "Buy" consensus rating for LifeStance Health Group, with a consensus price target of $10.00.
